HOPO's chelator featured in Cancer Cytopathology
The development of HOPO Therapeutics’ lead drug candidate as a medical countermeasure for use in a radiological disaster scenario is detailed in an interview with co-founder
Rebecca Abergel, Ph.D.
, a journal of the
American Cancer Society
. An effective treatment for removal of radioactive and other heavy metals from the body, its performance in preclinical trials has been vastly superior to any other chelating agent.
Learn more about our science